5121-34-6

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-amino-3-methoxybenzoate is used as an intermediate in the synthesis of pharmaceuticals for its role in the production of various medicines, such as pain relievers and anti-inflammatory drugs. Its unique chemical structure allows it to be a key component in the development of these therapeutic agents.
Used in Agrochemical Industry:
Methyl 2-amino-3-methoxybenzoate is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of products that enhance crop protection and management. Its versatility in chemical reactions makes it a valuable component in the formulation of various agrochemical products.

Upstream product

• 186581-53-3 diazomethane 
• 548-93-6 3-hydroxyanthranilic acid 
• 67-56-1 methanol 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 4771-47-5 3-chloro-2-nitro-benzoic acid 
• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 5368-81-0 methyl 3-methoxybenzoate 
• 84575-27-9 7-methoxy-1H-indole-2,3-dione 
• 115378-20-6 3-methoxy-2-pivalamidobenzoic acid 
• 90-04-0 2-methoxy-phenylamine 
• 33768-49-9 N-(2-methoxyphenyl)pivalamide 
• 80-11-5 N-methyl-N-nitrosotoluene-p-sulfonamide 

Downstream Products

• 99545-46-7 3-Methoxy-2-(ω-methoxycarbonyl-propionylamino)-benzoesaeure-methylester 
• 204686-75-9 (R)-N-(2-methoxy-6-methoxycarbonylphenyl)-5-methyl-4-(tetrahydropyran-2-yloxy)hexanamide 
• 704912-40-3 7-methoxyquinolino[2',3':3,4]pyrrolo[2,1-b]quinazolin-11(13H)-one 
• 76745-47-6 3-methoxyanthranilic hydrazide 
• 906095-44-1 methyl 2-amino-5-chloro-3-methoxybenzoate 
• 906095-57-6 methyl 2-amino-5-iodo-3-methoxybenzoate 
• 58026-22-5 2-amino-5-chloro-3-methoxybenzoic acid 
• 154288-09-2 4-chloro-8-methoxyquinazoline 
• 16064-27-0 8-methoxy-quinazolin-4(3H)-one 
• 864292-36-4 6-bromo-2,4-dichloro-8-methoxyquinazoline 
• 1415470-79-9 (2S,3R,4R,5S,6R)-2-(6-(4-ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1415470-82-4 (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1415470-83-5 (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 697762-67-7 methyl 5-bromo-2-chloro-3-methoxybenzoate 

Relevant academic research and scientific papers

Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes

Sodium-dependent glucose co-transporter 2 (SGLT2) has emerged as a promising drug target for the treatment of type 2 diabetes, and recently, several SGLT2 inhibitors have been approved for clinical use. A series of molecules with a C-aryl glucoside scaffo

Discovery of VU6027459: A First-in-Class Selective and CNS Penetrant mGlu7Positive Allosteric Modulator Tool Compound

Herein, we report the discovery of the first selective and CNS penetrant mGlu7 PAM (VU6027459) derived from a "molecular switch"within a selective mGlu7 NAM chemotype. VU6027459 displayed CNS penetration in both mice (Kp = 2.74) and rats (Kp= 4.78), it was orally bioavailable in rats (%F = 69.5), and undesired activity at DAT was ablated.

Evolution of N-Heterocycle-Substituted Iodoarenes (NHIAs) to Efficient Organocatalysts in Iodine(I/III)-Mediated Oxidative Transformations

The reactivity of ortho-functionalized N-heterocycle-substituted iodoarenes (NHIAs) as organocatalysts in iodine(I/III)-mediated oxidations was systematically investigated in the α-tosyloxylation of ketones as the model reaction. During a systematic catalyst evolution, it was found that NH-triazoles and benzoxazoles have the most significant positive influence on the reactivity of the central iodine atom. A further catalyst improvement which focused on the substitution pattern of the arene revealed a remarkable ortho-effect. By introduction of an o-OMe group we were able to generate a novel NHIA with a so far unseen catalytic efficiency. This new catalyst is not only easy to synthesize but also enabled the α-tosyloxylation of carbonyl compounds at the lowest reported catalyst loading of only 1 mol%. Finally, the performance of this iodine(I) catalyst was successfully demonstrated in intramolecular oxidative couplings of biphenyls and oxidative rearrangements. (Figure presented.).

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES

Therapeutic combinations of hepatitis B virus (HBV) vaccines and quinazoline derivatives are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

BENZOXABOROLE COMPOUNDS AND FORMULATIONS THEREOF

A benzoxaborole formulation composition including a benzoxaborole, a non-ionic surfactant, or a non-ionic and ionic surfactant mixture, and a carrier is described herein. At least one of the non-ionic surfactant, the non-ionic and ionic surfactant mixture

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.

2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF

This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), R1 is a C3-8alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C1-3 alkyl, or C1-3 alkoxy, the carbon of R1 bonded to the amine in the 4-position of the quinazoline is in (R)-configuration, R2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, R3 is hydrogen or deuterium, R4 is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C4-7 heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C4-7 heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, R5 is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R2, R3, R4 and R5 is not hydrogen.

METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which

Distinct urinary metabolite profiles of two pharmacologically active N-methylanthranilates: Three approaches to xenobiotic metabolite identification

Two volatile alkaloids, isopropyl N-methylanthranilate (IMA) and methyl N-methylanthranilate (MMA), present in the human diet and cosmetic products, were recently demonstrated to possess important pharmacological activities. While MMA is considered to be phototoxic, there is scarce data on the toxicity of IMA. Herein, we analyzed urinary metabolites of IMA and MMA in rats (200 mg kg?1, i.p., 7 days) by combining three different approaches: 1) preparative chromatography, 2) synthesis, and 3) SPR. The preparative approach, Sephadex LH-20 chromatography of the extract of urine samples of IMA treated animals, in conjunction with NMR, enabled the identification of 16 different anthranilate derivatives, among which products of aromatic core hydroxylation (isopropyl 5-hydroxy-N-methylanthranilate, isopropyl 5-hydroxyantranilate, isopropyl 3-hydroxyantranilate) were the major ones. The first application of the synthetic/combinatorial approach led to a successful identification of MMA metabolites, where 2-(methylamino)benzamide and N-methylanthranilic acid were the principal ones, among 14 others. Generally, MMA and IMA undergo analogous biotransformation pathways; however, MMA predominantly underwent chemical conversions of the ester group, i.e. transformation into derivatives of anthranilamide and anthranilic acid, while the major metabolic pathway of IMA was hydroxylation of the aromatic core. Additionally, pathohistological examinations revealed no signs of liver toxicity, or other signs of toxicity.

NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF

Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.